证券代码：300298 证券简称：三诺生物 公告编号：2025-065 债券代码：123090 债券简称：三诺转债 三诺生物传感股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）分别于 2025 年 4 月 18 日、 议并通过《关于变更注册资本暨修订〈公司章程〉部分条款的议案》，同意公司 注册资本由人民币 564,221,835 元变更为人民币 560,266,088 元，对《公司章程》 相应条款依法进行修订。具体内容详见公司于 2025 年 4 月 21 日在中国证监会指 定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn）上披露的《关于变更 注册资本暨修订 <公司章程> 的公告》 （公告编号：2025-026）。 鉴于公司于 2025 年 7 月 10 日在中国证券登记结算有限责任公司深圳分公 司办理完成 3,999,287 股回购股份的注销事宜，公司总股本由 564,265,375 股变更 为 560,266,088 股。具体内容详见公司于 2025 年 7 月 11 日在中国证 ...

特此公告。 深圳市尚荣医疗股份有限公司 董 事 会 年度业绩预告》详见同日公司在巨潮资讯网（www.cninfo.com.cn）上的披露。公 司对上述更正事项给投资者带来的不便深表歉意。公司今后将进一步加强审核工 作。 | 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-038 | | --- | | 深圳市尚荣医疗股份有限公司 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 | | 假记载、误导性陈述或重大遗漏。 | | 深圳市尚荣医疗股份有限公司（以下简称"公司"）于2025年7月12日披露 | | 的《2025年半年度业绩预告》（公告编号：2025-037）。因工作人员疏忽，上述 | | 公告中的部分内容出现了错误，现予以更正。本次更正不涉及对原公告的实质性 | | 的变更，具体如下： | | 更正前： | | 一、本期业绩预计情况 | | （一）业绩预告期间 | | （二）业绩预告情况 | | ? 预计净利润为负值 | | 项 目 本报告期 上年同期 | | 亏损：700 万元— 950 万元 | | 归属于上市公司 | | 盈利：1402.66 万元 | | ...

Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and has publicly disclosed the list of proposed incentive recipients, following relevant legal and regulatory requirements [1][2][3]. Disclosure and Verification - The company disclosed the draft of the 2025 Restricted Stock Incentive Plan and related documents on July 1, 2025, on the designated information disclosure website [1]. - The internal public notice of the proposed incentive recipients took place from July 2 to July 11, 2025 [1]. Verification Process - The Board's Compensation and Assessment Committee verified the proposed incentive recipients' qualifications, including their employment contracts and positions within the company [2]. - The verification confirmed that all proposed recipients meet the qualifications set forth by relevant laws and the company's articles of association [3]. Committee's Verification Opinion - The proposed incentive recipients are qualified according to the Company Law and other relevant regulations [3]. - None of the proposed recipients fall under the disqualifying conditions outlined in the management regulations [3]. - The recipients include senior management, middle management, grassroots management, and core technical personnel, excluding major shareholders and independent directors [3].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant price increase in the next 6-12 months [4]. Core Insights - The company anticipates a revenue of 708 million to 787 million RMB for the first half of 2025, representing a year-on-year decline of 10% to flat growth. The net profit attributable to the parent company is expected to be between 304 million and 361 million RMB, reflecting a year-on-year decrease of 25% to 11% [2]. - The company has successfully launched several innovative products, including the Cratos branched aortic stent system and the Tipspear transjugular intrahepatic portosystemic shunt kit, which have received regulatory approval [3]. - The international business has expanded to over 40 countries, with significant certifications obtained for key products, indicating a strong international growth strategy [3]. Performance Analysis - The company experienced a temporary decline in performance due to price adjustments and market conditions in the domestic market, but core products have shown resilience and recovery in the second quarter [2]. - Revenue growth is projected to rebound significantly in the coming years, with expected net profits of 606 million, 794 million, and 965 million RMB for 2025, 2026, and 2027, respectively, indicating growth rates of 21%, 31%, and 22% [4][9]. Financial Projections - The company’s revenue is forecasted to grow from 1,206 million RMB in 2024 to 2,505 million RMB in 2027, with a compound annual growth rate (CAGR) of approximately 21.08% [9]. - The projected net profit margins are expected to improve, with net profit margins of 41.6% in 2024 and 38.5% in 2027 [10]. Market Sentiment - Recent market analysis shows a strong preference for "Buy" ratings, with a significant number of recommendations over the past months indicating positive sentiment towards the company's stock [11].

Core Viewpoint - The article discusses the implications of the EU's recent ban on Chinese medical device participation in its procurement processes, highlighting the rapid growth of China's medical device industry and the potential for retaliatory measures from China [3][4]. Summary by Sections EU-China Medical Trade Dynamics - In 2024, the trade scale of medical devices between China and the EU is projected to be $37.04 billion, with China importing $28.04 billion (a 6.09% decrease year-on-year) and exporting $9 billion (a 12% increase) [5]. Product Composition and Market Trends - China's exports of high-end medical equipment to the EU have seen significant growth, with endoscopes increasing by 294% over four years. Advanced models like 7.0T MRI and 640-slice CT are gaining market share in Germany and France due to competitive pricing [6]. - Despite the EU being China's largest source of medical device imports, the market share of foreign brands is declining as domestic brands gain traction [6]. Rise of Domestic Brands - The domestic market for MRI machines has reached a localization rate of 35.1% in 2024, with CT machines seeing significant increases in installation rates in tertiary hospitals. Domestic brands have reduced PET-CT examination costs by approximately 25% [8]. - By early 2025, about 70% of medical linear accelerators approved by the National Medical Products Administration are domestically produced, showcasing the rapid advancement of local manufacturing capabilities [8]. Factors Supporting Domestic Growth - The rise of domestic brands is attributed to favorable policies like "Made in China 2025," which mandates the application of domestic medical devices in public hospitals. Regulatory support for emerging technologies has also accelerated domestic innovation [11]. - Domestic medical devices are iterating faster than imports, with significant advancements in technology and design tailored to local needs [12]. Innovations and Future Prospects - China is leading in brain-computer interface technology and surgical robotics, with unique innovations such as five-arm robots and non-inflated surgery techniques [13]. - The article emphasizes the potential for Chinese medical devices to become a global benchmark, driven by a large domestic market and rapid technological advancements [14].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Gaush Meditech Ltd 高視醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股 份 代 號：2407） 自願公告 一次性使用超聲乳化玻切沖洗吸引管路套件獲得 中國醫療器械註冊證 本公告由高視醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 高視醫療科技有限公司 主席兼執行董事 高鐵塔先生 香港，2025年7月14日 截至本公告日期，董事會包括主席兼執行董事高鐵塔先生，執行董事劉新偉先生、趙新禮先 生、張建軍先生及李文奇女士，非執行董事David Guowei Wang博士，以及獨立非執行董事馮 昕先生、王立新先生及陳帆城先生。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司附屬公司深圳高視科技 ...

南卫股份（603880）公告，公司2025年半年度净利润为负值。预计2025年半年度归属于母公司所有者的 净利润为-1600万元到-1200万元，归属于母公司所有者的扣除非经常性损益后的净利润为-1800万元 到-1400万元。公司部分产品原材料价格上涨，导致成本增加。受国际贸易政策、地缘政治及物流运输 等因素影响，导致部分产品订单受限，对收入和利润产生较大影响。 ...

Core Viewpoint - Kefu Medical (SZ301087) plans to accelerate its global strategy by issuing H-shares and listing on the Hong Kong Stock Exchange to enhance its overseas business capabilities and brand recognition [2] Group 1: Company Overview - Kefu Medical was established in 2009 and focuses on providing medical health products and one-stop solutions, covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy [2] - The company has developed into a full lifecycle personal health management enterprise integrating R&D, production, sales, and services [2] Group 2: Financial Performance - Kefu Medical's revenue for 2022, 2023, and 2024 is projected to be 2.977 billion, 2.854 billion, and 2.983 billion CNY respectively, with net profit attributable to the parent company at 302 million, 254 million, and 312 million CNY [3] - In Q1 2025, Kefu Medical reported revenue of 738 million CNY, a year-on-year decrease of 8.59%, and a net profit of 91.43 million CNY, down 9.68% year-on-year [4] Group 3: Management and Compensation - Zhang Min and Nie Juan are the actual controllers of Kefu Medical, with Zhang serving as the chairman and president, and Nie as the general manager [5] - Zhang Min's compensation from Kefu Medical from 2020 to 2024 was 380,900, 377,300, 493,400, 493,600, and 1,350,000 CNY, with a year-on-year increase of 173.5% in 2024 [7][8] Group 4: Market Performance - As of July 14, Kefu Medical's stock price was 35.35 CNY, down 0.92%, with a total market capitalization of 7.391 billion CNY [9][10]

Core Points - The European Union (EU) has extended the suspension period for countermeasures against U.S. tariffs until early August in response to President Trump's threat of a 30% tariff on EU imports starting August 1 [1][4] - EU Commission President Ursula von der Leyen emphasized the importance of negotiations, stating that if no agreement is reached, the EU will prepare countermeasures [3][5] - French President Emmanuel Macron expressed strong opposition to the U.S. tariffs and called for the EU to demonstrate its commitment to defending its interests [4][5] Trade Relations - The total trade in goods and services between the EU and the U.S. is projected to reach €1.7 trillion in 2024, averaging €46 billion daily [7] - In 2024, the EU is expected to export €531.6 billion worth of goods to the U.S. while importing €333.4 billion, resulting in a trade surplus of €198.2 billion [7] - The EU's exports to the U.S. have increased by 5.5% compared to 2023, while imports have decreased by 4.0% [7] Negotiation Dynamics - Trump's administration is focused on reducing the trade surplus the EU has with the U.S., which is seen as a key objective behind the tariff threats [7][10] - The EU is exploring various trade relationships and is seeking to diversify its trade partnerships beyond the U.S. [10] - Macron's statements reflect the voice of EU member states, emphasizing the need for a united front against U.S. trade policies [6][5]

Group 1 - The core viewpoint is that brain-computer interface technology is a cutting-edge development direction globally, with Beijing making significant progress in the innovation and transformation of medical devices based on this technology [1] - The National Medical Products Administration (NMPA) will continue to closely monitor the research and development progress of medical devices in the brain-computer interface field [1] - The NMPA plans to collaborate with relevant departments to introduce supportive measures and provide targeted solutions to facilitate the market launch of brain-computer interface-based medical devices in China [1]